Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, 700032, India.
Eur J Med Chem. 2020 Sep 1;201:112559. doi: 10.1016/j.ejmech.2020.112559. Epub 2020 Jun 12.
The ongoing novel coronavirus disease (COVID-19) pandemic makes us painfully perceive that our bullet shells are blank so far for fighting against severe human coronavirus (HCoV). In spite of vast research work, it is crystal clear that the evident does not warrant the commercial blossoming of anti-HCoV drugs. In this circumstance, drug repurposing and/or screening of databases are the only fastest option. This study is an initiative to recapitulate the medicinal chemistry of severe acute respiratory syndrome (SARS)-CoV-2 (SARS-CoV-2). The aim is to present an exquisite delineation of the current research from the perspective of a medicinal chemist to allow the rapid development of anti-SARS-CoV-2 agents.
正在持续的新型冠状病毒病（COVID-19）大流行让我们痛苦地意识到，迄今为止，我们对抗严重人冠状病毒（HCoV）的“子弹”还没有着落。尽管进行了广泛的研究，但很明显，现有的证据还不能保证抗 HCoV 药物的商业繁荣。在这种情况下，药物重新定位和/或数据库筛选是唯一最快的选择。本研究旨在重温严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）的药物化学。目的是从药物化学家的角度对当前的研究进行精确的描述，从而使抗 SARS-CoV-2 药物能够快速开发。
